IChemE Honorary Fellowship given to EU parliament president
In recognition of his contribution to the process industries
IChemE Honorary Fellowships are reserved for distinguished individuals from the chemical and process industries who have made significant contributions to the field. An Honorary Fellowship is the most senior award bestowed by the Institution.
Richard Darton, IChemE past president and current president of the European Federation of Chemical Engineering (EFCE) presented Buzek with his certificate.
Buzek graduated from the mechanics and energy division of the Silesian University of Technology in Gliwice, Poland in 1963 before becoming a scientist in the chemical engineering institute of the Polish academy of sciences. He is also an honorary doctor of the universities in Seoul, South Korea and Dortmund, Germany.
Buzek is the author of approximately 200 research papers and has lectured at the Technical Universities of Silesia and Opole, Poland. He was also a co-founder of the Polish-German science network for energy and environment protection and founded the consortium for atmosphere protection in Silesia.
Buzek was founder of the Polonia School of Diplomacy and between 2002 and 2004 he was vice-rector of Polonia University. He served as prime minister of Poland from 1997–2001. Since 2004 he has been a member of the European Parliament.
Accepting the fellowship certificate, Buzek called for a better synergy between industry, academia and public authorities and said chemical engineers are leaders in the pursuit of solutions to major global challenges.
‘Everything is connected to the basic possibilities and science of chemical engineering, I am convinced that solutions to the challenges facing Europe will be found through research and applied innovation,’ he said.
IChemE ceo David Brown said he would echo Buzek’s call for more engineers and scientists to step forward into public life.
‘Society would be well served if they did so, as Jerzy Buzek has. It's great to have him as an Honorary Fellow of IChemE,’ he said.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio